Literature DB >> 3181218

Plasma levels of fluphenazine and prolactin in psychiatric patients.

T Kitamura1, D A McGovern, N W Imlah, D Wiles, A A Schiff.   

Abstract

A total of 100 patients receiving fluphenazine (FPZ) decanoate for at least 12 months (96 schizophrenics and 4 other diagnoses) were investigated for plasma levels of FPZ and prolactin on the day of injection (day 0) and 7 days later (day 7). The plasma FPZ level significantly correlated with the weekly dose of FPZ. The plasma FPZ level per weekly FPZ dose multiplied by 100 (the FPZ ratio) showed a 20-fold variation. The FPZ ratio was significantly higher in the day- and in-patients (hospital-patients) than in out-patients. The plasma prolactin level significantly correlated with the plasma FPZ level but the prolactin to FPZ ratio negatively correlated with the plasma FPZ level. The prolactin to FPZ ratio was lower in the hospital patients than in the out-patients. This may suggest either that the high prolactin to FPZ ratio is an indicator of the therapeutic efficacy of FPZ or that there are at least two biologically distinct subgroups, one with a sharp prolactin response to FPZ, therefore with good prognosis, and another with the reverse direction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3181218     DOI: 10.1007/bf00380974

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN: 0175-758X


  34 in total

1.  Prolactin responses to neuroleptics in normal and schizophrenic subjects.

Authors:  P H Gruen; E J Sachar; G Langer; N Altman; M Leifer; A Frantz; F S Halpern
Journal:  Arch Gen Psychiatry       Date:  1978-01

2.  Dopamine receptor sites in the anterior pituitary.

Authors:  P C Goldsmith; M J Cronin; R I Weiner
Journal:  J Histochem Cytochem       Date:  1979-08       Impact factor: 2.479

3.  The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients.

Authors:  J Denham; L Adamson
Journal:  Acta Psychiatr Scand       Date:  1971       Impact factor: 6.392

4.  A follow-up study of schizophrenic outpatients treated with depot-neuroleptics.

Authors:  J Tegeler; E Lehmann
Journal:  Prog Neuropsychopharmacol       Date:  1981

5.  Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.

Authors:  L E Hollister; D Y Kim
Journal:  Am J Psychiatry       Date:  1982-11       Impact factor: 18.112

6.  Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.

Authors:  G E Hogarty; N R Schooler; R Ulrich; F Mussare; P Ferro; E Herron
Journal:  Arch Gen Psychiatry       Date:  1979-11

7.  High doses of fluphenazine enanthate in schizophrenia. A controlled study.

Authors:  S J Dencker; R Johansson; L Lundin; U Malm
Journal:  Acta Psychiatr Scand       Date:  1978-05       Impact factor: 6.392

8.  Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.

Authors:  S R Hirsch; R Gaind; P D Rohde; B C Stevens; J K Wing
Journal:  Br Med J       Date:  1973-03-17

9.  Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Behavioral considerations.

Authors:  R Neborsky; D Janowsky; E Munson; D Depry
Journal:  Arch Gen Psychiatry       Date:  1981-02

10.  A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.

Authors:  B Wistedt
Journal:  Acta Psychiatr Scand       Date:  1981-07       Impact factor: 6.392

View more
  1 in total

Review 1.  Prolactin and psychopathology in schizophrenia: a literature review and reappraisal.

Authors:  Ravi Philip Rajkumar
Journal:  Schizophr Res Treatment       Date:  2014-03-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.